Archer, Ironbridge consider iNova Pharmaceuticals sale
Archer Capital and Ironbridge are looking to sell iNova Pharmaceuticals for A$700-850 million ($714-878 million). The private equity firms have appointed Greenhill Caliburn to advise on the sale process and would like to have a deal in place by the end of the year, The Wall Street Journal reported, citing people familiar with the situation.
iNova is a consumer healthcare and prescription business that operates in Australia, New Zealand, Africa and the Asia Pacific region. Archer and Ironbridge are said to have been contacted by foreign strategic...
More on Australasia
Latest News
Asian GPs slow implementation of ESG policies - survey
Asia-based private equity firms are assigning more dedicated resources to environment, social, and governance (ESG) programmes, but policy changes have slowed in the past 12 months, in part due to concerns raised internally and by LPs, according to a...
Singapore fintech start-up LXA gets $10m seed round
New Enterprise Associates (NEA) has led a USD 10m seed round for Singapore’s LXA, a financial technology start-up launched by a former Asia senior executive at The Blackstone Group.
India's InCred announces $60m round, claims unicorn status
Indian non-bank lender InCred Financial Services said it has received INR 5bn (USD 60m) at a valuation of at least USD 1bn from unnamed investors including “a global private equity fund.”
Insight leads $50m round for Australia's Roller
Insight Partners has led a USD 50m round for Australia’s Roller, a venue management software provider specializing in family fun parks.